NAD+ — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

NAD+ (Plus) Protocol Peptide Guide: SubQ, IV, IM, Oral & Pen Dosing (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols NAD+ (Plus) Dosing Guide: SubQ, IV, IM, Oral & Pen (2026) Protocol / Research Dosing Guide NAD+ (Plus) Dosing Guide: SubQ, IV, IM, Oral & Pen (2026) Plain-language NAD+ protocol covering every common research-context delivery route, vial reconstitution math, supplies by cycle length, side effects, evidence boundaries, and an evidence-aware comparison with oral NMN and NR precursors. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners NAD+ Buffered View Supplier Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status NAD+ Comparisons Related Protocols Blood Tests FAQ References NAD+ Quick Start NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. Your body uses it to turn food into cellular energy (ATP), to fuel DNA repair, and to power a family of longevity-related enzymes called sirtuins.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (8) · phenotypes (0)

evidence_reference, dosing_reference, safety_reference, mechanism, monitoring_reference, contraindication_reference

Findings (149) · awaiting review (116)

dosing · pending

Common research-context range: 250-500 mg per session weekly or bi-weekly; 500-1,000 mg per session in higher-dose clinic protocols.

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners NAD+ Buffered View Supplier Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status NAD+ Comparisons Related Protocols Blood Tests FAQ References NAD+ Quick Start NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell.

dosing · pending

It covers subcutaneous (SubQ) injection, intravenous (IV) infusion, intramuscular (IM) injecti

regulatory · pending

Status Injectable NAD+ is not FDA-approved as a therapeutic.

regulatory · pending

NAD+ injection is not FDA-approved.

dosing · pending

NAD+ Dosing Protocol & Schedule Choose the tab that matches the route you are researching.

dosing · pending

NAD+ dose ranges, scheduling notes, and evidence boundaries.

dosing · pending

Subcutaneous (SubQ) Intravenous (IV) Intramuscular (IM) Oral (NMN / NR) Intranasal / Sublingual Pen / Pre-mixed liquid Most practical injectable route for research-use planning at home settings.

dosing · pending

Common research-context range: 50-100 mg per injection, 2-3 times per week.

dosing · pending

Some titration models start at 50 mg once weekly for 4 weeks, then escalate to 100 mg weekly.

dosing · pending

Higher daily-loading models (100-200 mg daily for 7-10 days) appear in clinic protocols and are typically reserved for supervised settings.

dosing · pending

SubQ NAD+ Titration Reference Phase Assessment Dose 50 mg Frequency 1x weekly or 3x weekly Notes Inject slowly over 5-10 seconds; assess tolerance.

dosing · pending

Phase Titration Dose 75 mg Frequency 1-3x weekly Notes Increase by ~25 mg if assessment phase is well tolerated.

dosing · pending

Phase Standard maintenance Dose 100 mg Frequency 2-3x weekly Notes Morning timing is commonly preferred.

dosing · pending

Phase Loading (intensive) Dose 100-200 mg Frequency Daily for 7-10 days Notes Higher side-effect potential; supervised settings only.

dosing · pending

Phase Dose Frequency Notes Assessment 50 mg 1x weekly or 3x weekly Inject slowly over 5-10 seconds; assess tolerance.

dosing · pending

Titration 75 mg 1-3x weekly Increase by ~25 mg if assessment phase is well tolerated.

dosing · pending

Standard maintenance 100 mg 2-3x weekly Morning timing is commonly preferred.

dosing · pending

Loading (intensive) 100-200 mg Daily for 7-10 days Higher side-effect potential; super

dosing · pending

Some research-planning protocols cap weekly SubQ at ~300 mg without further evaluation.

outcome · pending

Injecting over 5-10 seconds (sometimes longer) usually reduces rate-dependent discomfort.

outcome · pending

Faster infusion rates increase the chance of acute discomfort like flushing, nausea, chest tightness, or headache.

dosing · pending

IV NAD+ Reference Ranges Approach Maintenance Per-session dose 250-500 mg Schedule Weekly to bi-weekly Notes Slow infusion over 2-4 hours.

dosing · pending

Approach Loading Per-session dose 500-1,000 mg Schedule 3-5 consecutive days, then weekly/monthly Notes Clinic-supervised only.

dosing · pending

Approach Per-session dose Schedule Notes Maintenance 250-500 mg Weekly to bi-weekly Slow infusion over 2-4 hours.

dosing · pending

Loading 500-1,000 mg 3-5 consecutive days, then weekly/monthly Clinic-supervised only.

dosing · pending

A 750 mg single 3-hour infusion has been reported to raise blood NAD+ ~398% over baseline in published pilot work.

dosing · pending

Common research-context range: 50-100 mg per injection, 1-3 times per week.

safety · pending

Most home research-planning protocols default to SubQ for tolerability, with IM reserved for clinician-led settings.

dosing · pending

Oral NAD+ Precursor Ranges from Published Trials Precursor Nicotinamide Riboside (NR) Dose 300-1,000 mg Frequency Daily Trial signal Multiple human RCTs raised blood NAD+ with favorable tolerability.

dosing · pending

Precursor Nicotinamide Mononucleotide (NMN) Dose 300-900 mg Frequency Daily Trial signal 60-day dose-response RCT showed dose-dependent NAD+ rise; 600 mg gave the largest effect.

dosing · pending

Precursor Dose Frequency Trial signal Nicotinamide Riboside (NR) 300-1,000 mg Daily Multiple human RCTs raised blood NAD+ with favorable tolerability.

dosing · pending

(NMN) 300-900 mg Daily 60-day dose-response RCT showed dose-dependent NAD+ rise; 600 mg gave the largest effect.

dosing · pending

Common research-context range: 50-200 mg per dose for intranasal sprays or sublingual troches, dosed daily or several times weekly.

dosing · pending

Pre-mixed liquid NAD+ is supplied as a sterile, pharmacy-compounded solution at a fixed concentration (commonly 100 mg/mL or 200 mg/mL).

dosing · pending

Pen devices use the same liquid in a multi-dose cartridge with a click-set delivery volume.

dosing · pending

Pen / Pre-mixed Reference Format Pre-mixed vial Concentration 100 mg/mL Dose example 50 mg Volume per dose 0.50 mL (50 units) Format Pre-mixed vial Concentration 100 mg/mL Dose example 100 mg Volume per dose 1.00 mL (100 units) Format Pre-mixed vial (high-conc.) Concentration 200 mg/mL Dose example 100 mg Volume per dose 0.50 mL (50 units) Format Pen device Concentration Set per device Dose example Click-set per dose Volume per dose Per device label Format Concentration Dose exam

dosing · pending

ple Volume per dose Pre-mixed vial 100 mg/mL 50 mg 0.50 mL (50 units) Pre-mixed vial 100 mg/mL 100 mg 1.00 mL (100 units) Pre-mixed vial (high-conc.) 200 mg/mL 100 mg 0.50 mL (50 units) Pen device Set per device Click-set per dose Per device label Always verify label concentration and pharmacy beyond-use dating.

mechanism · pending

ve clinic protocol Unlike receptor-based peptides, NAD+ is a coenzyme.

Processing

Processed into 27 searchable sections.